Free Trial
NASDAQ:LUNG

Pulmonx (LUNG) Stock Price, News & Analysis

Pulmonx logo
$2.68 -0.06 (-2.01%)
As of 02:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pulmonx Stock (NASDAQ:LUNG)

Key Stats

Today's Range
$2.66
$2.81
50-Day Range
$2.57
$3.77
52-Week Range
$2.50
$9.37
Volume
113,840 shs
Average Volume
304,967 shs
Market Capitalization
$107.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.53
Consensus Rating
Moderate Buy

Company Overview

Pulmonx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

LUNG MarketRank™: 

Pulmonx scored higher than 63% of companies evaluated by MarketBeat, and ranked 398th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pulmonx has only been the subject of 4 research reports in the past 90 days.

  • Read more about Pulmonx's stock forecast and price target.
  • Earnings Growth

    Earnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmonx is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmonx is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmonx has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pulmonx's valuation and earnings.
  • Percentage of Shares Shorted

    4.04% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pulmonx does not currently pay a dividend.

  • Dividend Growth

    Pulmonx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.04% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pulmonx has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Pulmonx this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for LUNG on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmonx insiders have sold 90.64% more of their company's stock than they have bought. Specifically, they have bought $71,362.00 in company stock and sold $136,044.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Pulmonx is held by insiders.

  • Percentage Held by Institutions

    91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pulmonx's insider trading history.
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Stock News Headlines

Why Volatility Keeps Coming Back — And How I Trade It
Volatility isn’t the enemy — it’s the opportunity. While most traders panic during market swings, Jeff Clark uses a three-step method to target quick wins from VIX spikes and sudden price moves. It works in any market direction… and he’s showing how it works in a free video, available now.
Pulmonx Corporation (LUNG) Stock Forecasts
See More Headlines

LUNG Stock Analysis - Frequently Asked Questions

Pulmonx's stock was trading at $6.79 at the beginning of the year. Since then, LUNG shares have decreased by 60.6% and is now trading at $2.6750.

Pulmonx Corporation (NASDAQ:LUNG) issued its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $22.54 million for the quarter, compared to analysts' expectations of $22.03 million. Pulmonx had a negative net margin of 65.27% and a negative trailing twelve-month return on equity of 63.69%.
Read the conference call transcript
.

Pulmonx (LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

Last Earnings
5/07/2025
Today
7/10/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUNG
CIK
1127537
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$4.15
Potential Upside/Downside
+322.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$56.39 million
Pretax Margin
-64.76%

Debt

Sales & Book Value

Annual Sales
$87.47 million
Price / Cash Flow
N/A
Book Value
$2.17 per share
Price / Book
1.26

Miscellaneous

Free Float
37,520,000
Market Cap
$109.90 million
Optionable
Optionable
Beta
0.45
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:LUNG) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners